{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:58:07Z","timestamp":1777348687852,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"This work was supported by Allergan (before its acquisition by AbbVie)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s40121-021-00568-7","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T14:02:53Z","timestamp":1639490573000},"page":"423-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials"],"prefix":"10.1007","volume":"11","author":[{"given":"Pedro L.","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urania","family":"Rappo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Akinapelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S.","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sailaja","family":"Puttagunta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"568_CR1","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1021\/ja208755j","volume":"134","author":"NJ Economou","year":"2012","unstructured":"Economou NJ, Nahoum V, Weeks SD, et al. A carrier protein strategy yields the structure of dalbavancin. J Am Chem Soc. 2012;134:4637\u201345.","journal-title":"J Am Chem Soc"},{"key":"568_CR2","unstructured":"Dalvance\u00ae (dalbavancin). Full Prescribing Information. Parsippany: Durata Therapeutics US Ltd.; 2021."},{"key":"568_CR3","unstructured":"Xydalba (dalbavancin). Summary of product characteristics. Amsterdam: Durata Therapeutics International BV; 2017."},{"key":"568_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/cid\/civ982","volume":"62","author":"MW Dunne","year":"2016","unstructured":"Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62:545\u201351.","journal-title":"Clin Infect Dis"},{"key":"568_CR5","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169\u201379.","journal-title":"N Engl J Med"},{"key":"568_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/jac\/dkv303","volume":"71","author":"RE Mendes","year":"2016","unstructured":"Mendes RE, Castanheira M, Farrell DJ, et al. Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011\u201313). J Antimicrob Chemother. 2016;71:276\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"568_CR7","doi-asserted-by":"publisher","first-page":"ii25","DOI":"10.1093\/jac\/dki008","volume":"55","author":"MB Dorr","year":"2005","unstructured":"Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother. 2005;55:ii25-30.","journal-title":"J Antimicrob Chemother"},{"key":"568_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40264-015-0374-9","volume":"39","author":"MW Dunne","year":"2016","unstructured":"Dunne MW, Talbot GH, Boucher HW, Wilcox M, Puttagunta S. Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies. Drug Saf. 2016;39:147\u201357.","journal-title":"Drug Saf"},{"key":"568_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1086\/427283","volume":"40","author":"I Raad","year":"2005","unstructured":"Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis. 2005;40:374\u201380.","journal-title":"Clin Infect Dis"},{"key":"568_CR10","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1086\/497271","volume":"41","author":"LE Jauregui","year":"2005","unstructured":"Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41:1407\u201315.","journal-title":"Clin Infect Dis"},{"key":"568_CR11","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/jac\/dki355","volume":"56","author":"AF Shorr","year":"2005","unstructured":"Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother. 2005;56:923\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"568_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler","year":"2006","unstructured":"Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653\u201365.","journal-title":"N Engl J Med"},{"key":"568_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1086\/595686","volume":"48","author":"MH Wilcox","year":"2009","unstructured":"Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase\u00a03 study. Clin Infect Dis. 2009;48:203\u201312.","journal-title":"Clin Infect Dis"},{"key":"568_CR14","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ijantimicag.2019.08.007","volume":"54","author":"AC Streifel","year":"2019","unstructured":"Streifel AC, Sikka MK, Bowen CD, Lewis JS 2nd. Dalbavancin use in an academic medical centre and associated cost savings. Int J Antimicrob Agents. 2019;54:652\u20134.","journal-title":"Int J Antimicrob Agents"},{"key":"568_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","volume":"18","author":"C Hidalgo-Tenorio","year":"2019","unstructured":"Hidalgo-Tenorio C, Vinuesa D, Plata A, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by Gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019;18:30.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"568_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ijid.2019.12.008","volume":"91","author":"A Hakim","year":"2020","unstructured":"Hakim A, Braun H, Thornton D, Strymish J. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: a case report. Int J Infect Dis. 2020;91:202\u20135.","journal-title":"Int J Infect Dis"},{"key":"568_CR17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ijantimicag.2019.08.006","volume":"54","author":"A Dinh","year":"2019","unstructured":"Dinh A, Duran C, Pavese P, et al. French national cohort of first use of dalbavancin: a high proportion of off-label use. Int J Antimicrob Agents. 2019;54:668\u201372.","journal-title":"Int J Antimicrob Agents"},{"key":"568_CR18","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/cid\/ciy279","volume":"67","author":"S Tobudic","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis. 2018;67:795\u20138.","journal-title":"Clin Infect Dis"},{"key":"568_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijid.2018.07.016","volume":"76","author":"BM Jones","year":"2018","unstructured":"Jones BM, Keedy C, Wynn M. Successful treatment of Enterococcus faecalis bacteremia with dalbavancin as an outpatient in an intravenous drug user. Int J Infect Dis. 2018;76:4\u20135.","journal-title":"Int J Infect Dis"},{"key":"568_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","volume":"51","author":"E Bouza","year":"2018","unstructured":"Bouza E, Valerio M, Soriano A, et al. Dalbavancin in the treatment of different Gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51:571\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"568_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/jcpt.12306","volume":"40","author":"JC Cho","year":"2015","unstructured":"Cho JC, Estrada SJ, Beltran AJ, Revuelta MP. Treatment of methicillin-sensitive Staphylococcus aureus bacteremia secondary to septic phlebitis using dalbavancin. J Clin Pharm Ther. 2015;40:604\u20136.","journal-title":"J Clin Pharm Ther"},{"key":"568_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","volume":"8","author":"JT Bork","year":"2019","unstructured":"Bork JT, Heil EL, Berry S, et al. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive Gram-positive infections. Infect Dis Ther. 2019;8:171\u201384.","journal-title":"Infect Dis Ther"},{"key":"568_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s15010-019-01379-2","volume":"48","author":"A Ciccullo","year":"2020","unstructured":"Ciccullo A, Giuliano G, Segala FV, et al. Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection. Infection. 2020;48:309\u201310.","journal-title":"Infection"},{"key":"568_CR24","doi-asserted-by":"publisher","first-page":"ofz274","DOI":"10.1093\/ofid\/ofz274","volume":"6","author":"T Morrisette","year":"2019","unstructured":"Morrisette T, Miller MA, Montague BT, et al. Long-acting lipoglycopeptides: \u201clineless antibiotics\u201d for serious infections in persons who use drugs. Open Forum Infect Dis. 2019;6:ofz274.","journal-title":"Open Forum Infect Dis"},{"key":"568_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz028","author":"C Bryson-Cahn","year":"2019","unstructured":"Bryson-Cahn C, Beieler AM, Chan JD, Harrington RD, Dhanireddy S. Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population. Open Forum Infect Dis. 2019. https:\/\/doi.org\/10.1093\/ofid\/ofz028.","journal-title":"Open Forum Infect Dis"},{"key":"568_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","volume":"81","author":"S Wunsch","year":"2019","unstructured":"Wunsch S, Krause R, Valentin T, et al. Multicenter clinical experience of real life dalbavancin use in Gram-positive infections. Int J Infect Dis. 2019;81:210\u20134.","journal-title":"Int J Infect Dis"},{"key":"568_CR27","unstructured":"Antibacterial Resistance Leadership Group. DOTS: Dalbavancin as an option for treatment of S.\u00a0aureus bacteremia. National Institute of Allergy and Infectious Diseases. 2021. https:\/\/arlg.org\/studies-in-progress. Accessed 15 Feb 2021."},{"key":"568_CR28","unstructured":"US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. 2021. https:\/\/www.fda.gov\/files\/drugs\/published\/Acute-Bacterial-Skin-and-Skin-Structure-Infections---Developing-Drugs-for-Treatment.pdf. Accessed 15 Feb 2021."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00568-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-021-00568-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00568-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T17:42:56Z","timestamp":1644946976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-021-00568-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["568"],"URL":"https:\/\/doi.org\/10.1007\/s40121-021-00568-7","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"assertion":[{"value":"16 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}